{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:45:28Z","timestamp":1792586728447,"version":"4.5.0"},"reference-count":54,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>Elexacaftor\/Tezacaftor\/Ivacaftor (ELX\/TEZ\/IVA) is a new CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) modulator treatment, used over the last few years, which has shown an improvement in different clinical outcomes in patients with cystic fibrosis (CF). The objective of this study was a systematic research of the literature on the efficacy and safety of this CFTR modulator on patients with CF. A search of Pubmed was conducted for randomized clinical trials and observational studies published from 2012 to September 2022. The included full manuscripts comprised nine clinical trials and 16 observational studies, whose participants were aged \u226512 years or were children 6\u201311 years old with at least one Phe508del mutation and\/or advanced lung disease (ALD). These studies reported that ELX\/TEZ\/IVA has a significant positive effect on the lung function of patients with CF, by ameliorating parameters such as FEV1, LCI, pulmonary exacerbations or sweat chloride concentration, increasing BMI and improving quality of their life. Its role in cystic fibrosis-related diabetes (CFRD) is not yet clear. It was found that this new CFTR modulator has an overall favorable safety profile, with mild to moderate adverse events. Further studies are needed for a deeper understanding of the impact of CFTR modulators on other CF manifestations, or the possibility of treating with ELX\/TEZ\/IVA CF patients with rare CFTR mutations.<\/jats:p>","DOI":"10.3390\/children10030554","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T05:53:44Z","timestamp":1678859624000},"page":"554","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6554-1735","authenticated-orcid":false,"given":"Nikoletta","family":"Kapouni","sequence":"first","affiliation":[{"name":"Pediatric Allergy and Respiratory Unit, 3rd Department of Pediatrics, \u201cAttikon\u201d University Hospital, National and Kapodistrian University of Athens, School of Medicine, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Moustaki","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Department, \u201cAgia Sofia\u201d Children\u2019s Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7632-1159","authenticated-orcid":false,"given":"Konstantinos","family":"Douros","sequence":"additional","affiliation":[{"name":"Pediatric Allergy and Respiratory Unit, 3rd Department of Pediatrics, \u201cAttikon\u201d University Hospital, National and Kapodistrian University of Athens, School of Medicine, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Loukou","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Department, \u201cAgia Sofia\u201d Children\u2019s Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,15]]},"reference":[{"key":"ref_1","unstructured":"Cystic Fibrosis Foundation Patient Registry (2023, January 06). Annual Data Report 2021. Available online: https:\/\/www.cff.org\/sites\/default\/files\/2021-11\/Patient-Registry-Annual-Data-Report.pdf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: A global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"113195","DOI":"10.1016\/j.ejmech.2021.113195","article-title":"Modulators of CFTR. Updates on clinical development and future directions","volume":"213","author":"Bardin","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","article-title":"Progress in therapies for cystic fibrosis","volume":"4","author":"Amaral","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/17476348.2021.1855980","article-title":"Development of elexacaftor-tezacaftor-ivacaftor: Highly effective CFTR modulation for the majority of people with cystic fibrosis","volume":"15","author":"Middleton","year":"2021","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1002\/ppul.25627","article-title":"Review of CFTR modulators 2020","volume":"56","author":"Goetz","year":"2021","journal-title":"Pediatr. Pulmonol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Liberati, A., and Altman, D.G. (2009). The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. PLoS Med., 6.","DOI":"10.1371\/journal.pmed.1000100"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","article-title":"Efficacy and safety of elaxacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: A 24-week, multicenter, randomised, double-blind, active-controlled, phase 3b trial","volume":"10","author":"Sutharsan","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Migliorisi, G., and Collura, M. (2022). Elexacaftor-Tezacaftor-Ivacaftor as a Final Frontier in the Treatment of Cystic Fibrosis: Definition of the Clinical and Microbiological Implications in a Case-Control Study. Pharmaceuticals, 15.","DOI":"10.20944\/preprints202204.0114.v1"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple Therapy for Cystic Fibrosis Phe508del-Gating and Residual Function Genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","article-title":"Efficacy and Safety of Elexacaftor\/Tezacaftor\/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3B, Randomized, Placebo-Controlled Study","volume":"206","author":"Mall","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"877118","DOI":"10.3389\/fphar.2022.877118","article-title":"Elexacaftor-Tezacaftor-Ivacaftor Treatment in Cystic Fibrosis-Early results Obtained with the CF-Specific CFAbd-Score","volume":"13","author":"Mainz","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/cid\/ciac117","article-title":"The Rapid Reduction of Infection-Related Visits and Antibiotic Use Among People with Cystic Fibrosis After Starting Elexacaftor-Tezacaftor-Ivacaftor","volume":"75","author":"Miller","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/alr.22700","article-title":"Effect of highly effective modulator therapy on quality of life in adults with cystic fibrosis","volume":"11","author":"DiMango","year":"2021","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical Effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in People with Cystic Fibrosis","volume":"205","author":"Nichols","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","article-title":"Effects of Elexacaftor\/Tezacaftor\/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles","volume":"205","author":"Graeber","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1164\/rccm.202201-0219OC","article-title":"Effects of Elexacaftor\/Tezacaftor\/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two F508del Alleles","volume":"206","author":"Graeber","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 Open-Label Study of Elexacaftor\/Tezacaftor\/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"852551","DOI":"10.3389\/fped.2022.852551","article-title":"Short-Term Effects of Elexacaftor\/Tezacaftor\/Ivacaftor Combination on Glucose Tolerance in Young People with Custic Fibrosis\u2014An observational Pilot Study","volume":"10","author":"Korten","year":"2022","journal-title":"Front. Pediatr."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2021.09.001","article-title":"The effect of elexacftor\/tezacaftor\/ivacaftor (ETI) on glycemia in adults with cystic fibrosis","volume":"21","author":"Scully","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Piona, C., and Mozzillo, E. (2022). Impact of CFTR Modulators on Beta-Cell Function in Children and Young Adults with Cystic Fibrosis. J. Clin. Med., 11.","DOI":"10.3390\/jcm11144149"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jcf.2021.03.016","article-title":"Peripheral lung effect of elexacaftor\/tezacaftor\/ivacaftor in adult cystic fibrosis","volume":"21","author":"Stylemans","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jcf.2021.05.009","article-title":"Short-term effect of elexacaftor-tezacaftor-ivacaftor on lung function and transplant planning in cystic fibrosis patients with advanced lung disease","volume":"20","author":"Bermingham","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_29","first-page":"100829","article-title":"Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease","volume":"80","author":"Martin","year":"2021","journal-title":"Respir. Med. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"106646","DOI":"10.1016\/j.rmed.2021.106646","article-title":"Effectiveness and safety of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and advanced lung disease with Phe508del\/minimal function genotype","volume":"189","author":"Carnovale","year":"2021","journal-title":"Respir. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1002\/ppul.25980","article-title":"Elexacaftor\/tezacaftor\/ivacaftor in children aged 6-11 years with cystic fibrosis, at least one F508DEL allele, and advanced lung disease: A 24-week observational study","volume":"57","author":"Salvatore","year":"2022","journal-title":"Pediatr. Pulmonol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Carnovale, V., and Iacotucci, P. (2022). Elexacaftor\/Tezacaftor\/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study. J. Clin. Med., 11.","DOI":"10.3390\/jcm11041021"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7812\/TPP\/21.089","article-title":"The Effect of Elexacaftor\/Tezacaftor\/Ivacaftor on Hospitalisations and Intravenous Antibiotic Use","volume":"26","author":"Walter","year":"2022","journal-title":"Perm. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1136\/thoraxjnl-2020-216265","article-title":"Projecting the impact of triple CFTR modulator therapy on intravenous antibiotic requirements in cystic fibrosis using patient registry data combined with treatments effects from randomized trials","volume":"77","author":"Keogh","year":"2022","journal-title":"Thorax"},{"key":"ref_36","first-page":"100286","article-title":"The role of modulators in cystic fibrosis related diabetes","volume":"27","author":"Merjaneh","year":"2022","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Dagenais, R.V.E., and Su, V.C.H. (2020). Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review. J. Clin. Med., 10.","DOI":"10.3390\/jcm10010023"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jcf.2022.04.010","article-title":"Onset of systemic arterial hypertension after initiation of elexacftor\/tezacaftor\/ivacaftor in adults with cystic fibrosis: A case series","volume":"21","author":"Gramegna","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"806","DOI":"10.7326\/0003-4819-82-6-806","article-title":"Low blood pressure in young adults with cystic fibrosis: An effect on chronic salt loss in sweat?","volume":"82","author":"Lieberman","year":"1975","journal-title":"Ann. Intern. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","article-title":"Safety and Efficacy of Elexacaftor\/Tezacftor\/Ivacaftor for 24 weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial","volume":"203","author":"Griese","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jcf.2020.07.014","article-title":"Biliary disease and cholocystectomy after initiation of elexacftor\/ivacaftor\/tezacaftor in adults with cystic fibrosis","volume":"20","author":"Safirstein","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ccm.2015.11.004","article-title":"Gastointestinal disorders in cystic fibrosis","volume":"37","author":"Assis","year":"2016","journal-title":"Clin. Chest. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2003079","DOI":"10.1183\/13993003.03079-2020","article-title":"The efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor in patients with cystic fibrosis and advanced lung disease","volume":"57","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.jcf.2020.04.017","article-title":"Testicular pain following initiation of elexacaftor\/tezacaftor\/ivacaftor in males with cystic fibrosis","volume":"19","author":"Rotolo","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.jcjo.2021.04.018","article-title":"Papilledema and hypervitaminosis A after elexacaftor\/tezacaftor\/ivacaftor for cystic fibrosis","volume":"57","author":"Miller","year":"2022","journal-title":"Can. J. Ophtalmol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jcf.2021.10.002","article-title":"Mental status changes during elexacaftor\/tezacaftor\/ivacaftor therapy","volume":"21","author":"Heo","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.psym.2020.06.021","article-title":"Trikafta and Psychopathology in Cystic Fibrosis: A case Report","volume":"61","author":"Tindel","year":"2020","journal-title":"Psychosomatics"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jcf.2021.05.017","article-title":"A case of self-limited drug induced liver injury under treatment with elexacaftor\/tezacaftor\/ivacaftor: When it is worth taking the risk","volume":"20","author":"Stylemans","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Terlizzi, V., and Colangelo, C. (2021). Effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in Three Subjects with the Cystic Fibrosis Genotype Phe508del\/Unknown and Advanced Lung Disease. Genes, 2.","DOI":"10.3390\/genes12081178"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/jmedgenet-2016-103985","article-title":"Genotype\u2013phenotype correlation and functional studies in patients with cystic fibrosis bearing CFTR complex alleles","volume":"54","author":"Terlizzi","year":"2017","journal-title":"J. Med. Genet."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e1656","DOI":"10.1002\/mgg3.1656","article-title":"Ex vivo model predicted in vivo efficacy of CFTR modulator therapy in a child with rare genotype","volume":"9","author":"Terlizzi","year":"2021","journal-title":"Mol. Genet. Genom. Med."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Liu, Z., and Anderson, J.D. (2020). Human Nasal Epithelial Organoids for Therapeutic Development in Cystic Fibrosis. Genes, 11.","DOI":"10.3390\/genes11060603"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.celrep.2019.01.068","article-title":"Rectal Organoids Enable Personalized Treatment of Cystic Fibrosis","volume":"26","author":"Berkers","year":"2019","journal-title":"Cell Rep."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Gramegna, A., and Contarini, M. (2020). From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21165882"}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/10\/3\/554\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:55:39Z","timestamp":1760122539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/10\/3\/554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":54,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["children10030554"],"URL":"https:\/\/doi.org\/10.3390\/children10030554","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,15]]}}}